Teva's Vantrela Gets FDA Panel Nod For Three Abuse-Deterrent Claims
This article was originally published in The Pink Sheet Daily
Executive Summary
Hydrocodone extended-release product is an incremental improvement in deterring oral, intranasal and intravenous abuse, committee says.